摘要
National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)(1) was organized by the National Health Commission of the People’s Republic of China, led by the Cancer Hospital of the Chinese Academy of Medical Sciences, and jointly compiled by well-known experts across China. On the basis of the 2018version, the 2022 version of the guideline not only absorbs the updated content of the latest international guidelines.
